Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: david james who wrote (884)	4/25/2000 1:09:00 PM
From: tuck	Read Replies (2) \| Respond to of 1298

david & bosco, For some insight as to when folks inside know about earnings etc. versus when it is announced, note statement in today's ABGX earnings PR concerning CEGE's "approximately 12%" stake. If I'm not mistaken, it's been known for about a month that CEGE's stake is now closer to 8%. Does this mean everything in this PR was known over a month ago? Except that CEGE's stake has changed since its preparation and some editor didn't change it? Or does it simply mean that it was written recently from recently known data, but the writer was sloppy in ownership research? Hmmmm. Sloppy, anyway. I agree with David that JT milestones should happen in Q2. I'm debating writing calls here, but they could announce a late stage candidate deal any time. My guess is it will be a couple of months at earliest, though. Stock and technology prices will be in a range for a few months in biotech, IMO. So CEGE can take the time required to choose wisely. So I'm thinking June calls, then go naked or half naked. How much upside would come to CEGE from a favorable TKTX ruling? Even if TKTX wins, it'll still be a while before they get to market, right? Is TKTX closer to selling in Europe? If this doesn't come off the top of your head, I'll be glad to go find that info myself and post it, but it might be a couple of days. Cheers, Tuck

To: david james who wrote (884)	4/28/2000 2:56:00 PM
From: tuck	Read Replies (1) \| Respond to of 1298

david, Might be a while before CEGE gets U.S. TKTX revenue. They keep losing rounds in their patent dispute. I would speculate that at the very least they will have to pay some kind of license to AMGN, and that will offset their cheaper manufacturing costs. In another couple of months maybe there would be a ruling regarding an injunction on TKTX's right to manufacture Epogen at all. Apparently the trial is now set to move on to claims regarding manufacture. biz.yahoo.com Despite this, the positive press about gene therapy seems to outweigh this distant possibility. Which is fine with me. Analysis by someone with more legal/industry insight is welcome.